Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral Intuvax (ilixadencel) before nephrectomy followed by sunitinib vs sunitinib alone in metastatic renal cell carcinoma
2014-004510-28Phase 2Completed
- Sponsor
- Mendus
- Start
- Dec 2014
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ilixadencel in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Mendus. Primary endpoint: Overall survival from randomization. Started Dec 2014; status: completed.
02
Drugs
ilixadencel
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2014-004510-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004510-28.